Clinical Trials Logo

Clinical Trial Summary

This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.

Clinical Trial Description

Transfer of patients to alloHSCT after one cycle or after a subsequent cycle is considered as per protocol discontinuation and as premature treatment discontinuation. There will be a safety follow-up visit at 30 days after end of the last infusion. There will be efficacy follow-up until 6 months after end of therapy. In patients scheduled for SCT the 30-day safety-visit may be performed at the latest time point possible before initiation of subsequent treatment. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05182385
Study type Interventional
Source Goethe University
Contact GMALL Study Center
Phone +49 (0)69 - 6301
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date December 15, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03109093 - Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia Phase 2